Helex key facts
as of Oct 2026- Developer of first-in-class genomic medicines designed for renal indications, combining the promise of non-viral targeted delivery and genome editing for the kidney.
- Helex is valued at approximately $36.9M as of Oct 2026 (last reported valuation).
- It has raised $6.6M; the latest was Seed Round ($3.5M) in Oct 2025.
- Notable investors include SOSV, IndieBio, New York Ventures, Fondation Botnar, BlueHill Capital — 7 tracked in total.
- Status: Privately Held (backing).
Helex's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·Watch Helex: the Monday email on marks, rounds and moves
Helex funding rounds
No funding rounds for Helex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Helex valuation
Helex's last reported valuation was $36.9 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Helex investors
7 investors are on record for Helex, including SOSV, IndieBio, New York Ventures and Fondation Botnar.
About Helex
Developer of first-in-class genomic medicines designed for renal indications, combining the promise of non-viral targeted delivery and genome editing for the kidney. The company's platform is powered by data-driven deep-learning modeling using high-throughput next-generation sequencing data derived from the gene editing technology, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) edits on human cell lines to give reliable predictions and validate them in-house, enabling clients to accelerate the CRISPR-based drug research and cell and gene therapies market by a renal franchise of precise and scalable therapeutics.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Employees
- 23
- Website
- helex.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.